Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunomedics Inc announces multiple partial responses with IMMU-132 in Solid Cancers

Monday, 7 Apr 2014 11:00am EDT 

Immunomedics Inc:Says five patients reported a partial response as their best response, based on RECIST 1.1 criteria, in company's ongoing Phase I/II clinical trial of its investigational antibody-drug conjugate (ADC), IMMU-132, in patients with solid cancers.IMMU-132 is anti-TROP-2 antibody with SN-38, the active metabolite of irinotecan, linked to antibody.Says Two of 3 patients with small-cell lung cancer (SCLC), 2 of seven patients with triple- negative breast cancer, and 1 of the 11 patients with colorectal cancer were partial responders by at least one computer tomography (CT) assessment.In addition to these 5 partial responses, among 35 patients who had at least one response assessment by CT, 22 patients had stable disease as their best response, giving an overall disease control rate of 77 pct.Besides colorectal, triple-negative breast, and SCLC, the 35 CT-assessable patients include 14 other types of solid cancer.These patients had failed a median of 4 prior treatments, some including topoisomerase-I and -II inhibiting drugs, and in some cases are showing durable responses up to almost one year.Grade 3 or 4 adverse events (AE) 8 pct were neutropenia (31 pct), fatigue (10 pct), and diarrhea (8 pct), while mild AE ( > 20 pct) were reported for nausea, fatigue, alopecia, diarrhea and vomiting. 

Company Quote

26 Mar 2015